NEW YORK (GenomeWeb News) – MyoKardia, a San Francisco-based drug startup, has been launched with $38 million in Series A financing from Third Rock Ventures.

The firm is taking a genetically targeted approach to drug development, using a proprietary drug discovery platform that combines advances in cardiovascular genomics and heart muscle biology research. According to the firm, its approach will "leverage resident expertise in sarcomere genetics, in vivo and in vitro disease models, next-generation biochemical and biophysical assay development, and medicinal chemistry."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: caution urged in use of gene drives, and more.

NIH's Sally Rockey examines the tapped and untapped potential of the NIH peer reviewer pool.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."